ClinicalTrials.gg

Program

Pyridoxal Phosphate

Also written as “Pyridoxal 5'-Phosphate”, “(MC-1) Pyridoxal 5'-phosphate” and “(MC-1) Pyridoxal-5'-phosphate”.

Its studies are mostly in Myocardial Ischemia · Tardive Dyskinesia, led by Medicure.

Furthest: phase 3, since Nov 20, 20065 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Medicure52 open or runningphase 3since Nov 20, 2006Sep 8, 2005Sep 2027phase 3 · NCT04706013

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2005First study: phase 2 study in Myocardial IschemiaFirst studyNCT00157716 · 900 enrolled · United States, Canada
  2. Nov 20, 2006Phase 3 study in Myocardial IschemiaNCT00402506 · 3,000 enrolled · United States, Canada
  3. Jun 8, 2009Phase 2 study in Tardive DyskinesiaNCT00917293 · 53 enrolled · Canada, India
  4. Jan 8, 2021Phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT04706013 · 15 enrolled · United States, Australia
  5. Oct 28, 2026Phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT07928388 · 10 planned · United States, Australia

Ahead

  1. Sep 2027Primary completion: phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT04706013
  2. Jul 15, 2029Primary completion: phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT07928388

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07928388Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency · United States, Australia3RecruitingJul 15, 202910
NCT04706013Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency · United States, Australia3Active, not recruitingSep 202715
NCT00917293Tardive Dyskinesia · Canada, India2TerminatedAug 201253
NCT00402506Myocardial Ischemia · United States, Canada3Completed3,000
NCT00157716Myocardial Ischemia · United States, Canada2Completed900

How it is read

Names in the registry

  • “Pyridoxal 5'-Phosphate”, 2 entries
  • “Pyridoxal Phosphate”, 1 entry
  • “(MC-1) Pyridoxal 5'-phosphate”, 1 entry
  • “(MC-1) Pyridoxal-5'-phosphate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.